TABLE 2.
Summary of pooled proportions for efficacy and safety outcomes on fostamatinib. a
| Outcome | Contributing studies | Number of patients | Pooled proportion | 95% CI | I 2 c |
|---|---|---|---|---|---|
| Overall response | 2 | 162 | 0.70 | 0.62, 0.76 | 0% |
| Partial response | 4 | 139 | 0.48 | 0.36, 0.61 | 53% |
| Stable response | 4 | 139 | 0.28 | 0.16, 0.44 | 67% |
| Any adverse event b | 3 | 174 | 0.86 | 0.80, 0.91 | 0% |
| Severe adverse event b | 2 | 123 | 0.15 | 0.10, 0.22 | 0% |
| Adverse event causing treatment withdrawal b | 3 | 174 | 0.10 | 0.06, 0.15 | 0% |
| Any bleeding b | 2 | 123 | 0.08 | 0.03, 0.20 | 52% |
| Rescue therapy b | 4 | 190 | 0.30 | 0.24, 0.37 | 30% |
| Hypertension b | 4 | 190 | 0.24 | 0.13; 0.40 | 67% |
| Diarrhea b | 4 | 190 | 0.30 | 0.21, 0.40 | 43% |
| Nausea b | 4 | 190 | 0.16 | 0.10; 0.24 | 37% |
| Neutropenia b | 3 | 174 | 0.07 | 0.02; 0.21 | 64% |
| Dizziness b | 2 | 117 | 0.11 | 0.07; 0.18 | 0% |
| Fatigue b | 3 | 168 | 0.15 | 0.04; 0.44 | 87% |
| Abdominal pain | 3 | 89 | 0.09 | 0.04; 0.22 | 38% |
| Transaminitis b | 3 | 139 | 0.15 | 0.07; 0.29 | 61% |
| Infection b | 2 | 123 | 0.17 | 0.11; 0.24 | 0% |
Abbreviation: CI, confidence interval.
a
No data from case series or abstracts were included in this primary analysis.
b
Data from FIT‐1 and FIT‐2 were treated as one study in meta‐analysis.
c
The I 2 statistic may be biased when the number of contributing studies is small, and the 95% CI should be included in the interpretation of a point estimate.